8.2 Consequences of low health literacy.Table 8.3 Educational techniques to improve health literacy.Table 8.4 Cultural factors that affect health care.Table 8.5 Barriers to successful, culturally appropriate health care delive...Table 8.6 Common areas of cultural conflict.Table 8.7 ETHNIC(S) mnemonic for improving communication.
9 Chapter 9Table 9.1 The Health Maintenance Clinical Glidepath.
10 Chapter 10Table 10.1 Age‐related changes pertinent to geropharmacology.Table 10.2 Practical tool to identify drugs that interact with Cytochrome P...Table 10.3 Tools to aid in the reduction of inappropriate medication use an...Table 10.4 Mnemonics for medication management.
11 Chapter 11Table 11.1 International adverse events studies, showing data for older pat...Table 11.2 Methods of measuring errors and adverse events.Table 11.3 Methods of understanding errors and adverse events.Table 11.4 Examples of some cognitive biases and heuristics that commonly a...Table 11.5 The seven‐level framework.
12 Chapter 12Table 12.1 Dietary and nutrient biomarker patterns associated with cognitiv...
13 Chapter 14Table 14.1 Malnutrition criteria according to the GLIM consensus.Table 14.2 Distinguishing starvation from cachexia.Table 14.3 Comprehensive gerontological assessment (CGA) to address weight ...
14 Chapter 16Table 16.1 Medical factors related to insufficient nutrient or energy intak...Table 16.2 Medication and nutrient interactions.Table 16.3 Function, deficiency, age‐related changes, food sources, and sup...
15 Chapter 17Table 17.1 Oesophageal causes of dysphagia.Table 17.2 Causes of delayed gastric emptying.Table 17.3 Medications that affect gastrointestinal motility.
16 Chapter 19Table 19.1 Medications associated with faecal incontinence.Table 19.2 The assessment of faecal incontinence.
17 Chapter 20Table 20.1 Anatomical distribution of changes associated with constipation.Table 20.2 Medications commonly associated with constipation.Table 20.3 Medical conditions commonly associated with constipation.Table 20.4 Medications used in the treatment of constipation.
18 Chapter 21Table 21.1 Pancreatic endocrine tumours.
19 Chapter 23Table 23.1 Mechanisms and precipitating factors in DIC.Table 23.2 Laboratory diagnosis of DIC.
20 Chapter 24Table 24.1 Coagulation tests.Table 24.2 Causes of acquired platelet functional defects other than due to...Table 24.3 Causes of acquired coagulation defects.Table 24.4 Haemorrhagic vascular defects.Table 24.5 INR ranges in various conditions.Table 24.6 Thrombophilic conditions.
21 Chapter 25Table 25.1 Characteristics of bleeding risk assessment tools.Table 25.2 Usual and adjusted dosages for DOACs.
22 Chapter 26Table 26.1 Cytopenia thresholds according to the WHO 2016 Classification.Table 26.2 Classification scheme of myelodysplastic syndromes (MDS) in the ...Table 26.3 WHO 2016 classification.Table 26.4 Differential diagnosis of clonal or idiopathic cytopenias and my...Table 26.5 International Prognosis Scoring System (IPSS) for MDS.Table 26.6 IPSS Survival for MDS and evolution to AML.Table 26.7 Cytogenetic prognostic groups in the IPSS‐R.Table 26.8 Prognostic models for ESA response in MDS.
23 Chapter 27Table 27.1 WHO classification of peripheral blood and bone marrow findings ...Table 27.2 Revised International Prognosis Scoring System (IPSS‐R).Table 27.3 Cytogenetics MDS score in the Revised International Prognosis Scoring...Table 27.4 WHO (2016) classification of acute myeloid leukaemias.
24 Chapter 28Table 28.1 Association between cardiovascular disease and frailty.Table 28.2 Association between heart failure and risk factors from case/con...
25 Chapter 29Table 29.1 Causes of bradycardia.Table 29.2 Duration of ambulatory monitoring.Table 29.3 Characteristics of trials comparing ventricular and physiologica...Table 29.4 Randomized controlled trials of rate versus rhythm control in AF...Table 29.5 Factors that increase the risk of sotalol‐induced QT prolongatio...Table 29.6 CHA2DS2‐VASc risk factor‐based scoring system.Table 29.7 Common medications that interact with warfarin.
26 Chapter 30Table 30.1 Advantage and cautions with IHD medications in older people.Table 30.2 Considerations in older people with IHD.
27 Chapter 31Table 31.1 Cholesterol metabolism and ageing.Table